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Induction of Cell Cycle Arrest
and B Cell Terminal Differentiation
by CDK Inhibitor p18INK4c and IL-6
Leslie Morse,*§ Dongquan Chen,*†§ of inhibitors (review by Sherr and Roberts, 1995), of
which p21WAF1/CIP1 (El-Diery et al., 1993; Harper et al.,David Franklin,‡ Yue Xiong,‡
1993; Xiong et al., 1993) is the most extensively studied.and Selina Chen-Kiang*
p21 is expressed in differentiated cells of nearly all lin-*Department of Pathology
eages in vivo (Parker et al., 1995), and its activationCornell University Medical College
correlates with MyoD-mediated cell cycle arrest and1300 York Avenue
terminal muscle differentiation (Halevy et al., 1995).New York, New York 10021
However, p21 is not essential for development because†Department of Microbiology
mice appear normal in its absence (Deng et al., 1995).Mount Sinai School of Medicine
By comparison, ablation of the expression of p16 andNew York, New York 10029
p19 in the INK4a locus led to rapid development of soft-‡Department of Biochemistry and Biophysics
tissue tumors and B cell lymphomas in mice (SerranoThe University of North Carolina at Chapel Hill
et al., 1996). These findings support a role for CDK inhibi-Chapel Hill, North Carolina 27599
tors of the p16 family in the control of cell proliferation
in vivo, in particular in the B lineage. Negative regulation
of cell cycle progression by CDK inhibitors is mediatedSummary
primarily by inhibition of phosphorylation of pRb, the
physiologic substrate for CDK4 and CDK6 (Kato et al.,Cell cycle arrest and cell death are tightly coupled to
1993; Meyerson and Harlow, 1994; Matsushime et al.,terminal differentiation of B cells to plasma cells in
1994). In its hypophosphorylated form, pRb induces G1vivo. This process was recapitulated in vitro by stimu-
arrest by sequestering the E2F transcription factors re-lation of IgG-bearing human B lymphoblastoid cells
quired for S-phase entry (Goodrich et al., 1991; Nevins,with interleukin-6 (IL-6), which led to orderly cell cycle
1992). Emerging evidence further suggests that pRbarrest, differentiation, and apoptosis. In terminally dif-
may also have a role in cellular differentiation by func-ferentiated plasmacytoid cells, phosphorylation of
tioning as a coactivator for transcription regulators suchpRb was suppressed, correlating with the activation
as nuclear factor–IL-6 (NF–IL-6) (Chen et al., 1996) andof theD-type cyclin–dependent kinase (CDK) inhibitors
the glucocorticoid receptor (Singh et al., 1995). Accord-p18INK4c and p21WAF1/CIP1. The expression of CDK6, how-
ingly, pRb is required for embryonic development (Leeever, remained unchanged. Activation of p18 by IL-6
et al., 1992).was rapid, concomitant with marked enhancement of
The cytokine interleukin-6 (IL-6) is thought to play aits association with CDK6 and cell cycle arrest. Over-
major role in the differentiation and cell cycle control ofexpression of p18 in IgM-bearing lymphoblastoid cells,
late- stage B cells. Ectopic expression of IL-6 in BALB/cwhich differentiated in response to IL-6 but did not
mice results in c-myc translocation and plasma-cell tu-exit the cell cycle, reconstituted coupled differentia-
mors (plasmacytomas), as a result of accelerated termi-tion and cell cycle arrest. Thus, CDK inhibitors, in par-
nal differentiation of B lymphocytes or deregulated pro-ticular p18, are likely to play a pivotal role in controlling
liferation of plasma cells (Nordan and Potter, 1986;cell cycle arrest and cell death in terminal differentia-
Suematsu et al., 1989; Suematsu et al., 1992). Inductiontion of late-stage B cells to plasma cells via inhibition
of plasmacytoma by overexpression of IL-6, however,of pRb phosphorylation by CDK6.
is contingent on the genetic background, because in
other strains of mice only immunoglobulin G (IgG) plas-
Introduction macytosis was observed (Suematsu et al., 1989). The
response of B cells to IL-6 appears to depend also on
Terminal differentiation of mature B lymphocytes to
the stage of B cell development, because although IgM-
plasma cells is essential for humoral immune response
bearing cells develop normally, IgG and IgA secretion
restricted to the B lineage. It is antigen-specific and is profoundly impaired in IL-6–deficient mice (Kopf et
requires costimulation by T cells and cytokines (Paul al., 1994). Together, these results suggest that IL-6 is
and Seder, 1994). In vivo, plasma cells synthesize and critical for terminal differentiation of B lymphocytes in
secrete large amounts of immunoglobulin and then rap- vivo, in particular late- stage B cells after immunoglobu-
idly undergo cell death to terminate effectively the im- lin class switching. Consistent with this hypothesis, ma-
mune response. Thus, precise and timely withdrawal jor hallmarks of B cell terminal differentiation can be
from thecell cycle is crucial for Bcell terminal differentia- recapitulated in vitro by stimulation of activated IgG-
tion. Despite this understanding, little is known about bearing human B lymphocytes with IL-6 (Raynal et al.,
the mechanism that governs differentiation-coupled cell 1989; Natkunam et al., 1994). These include marked
cycle arrest and death in B cell terminal differentiation. increases in immunoglobulin synthesis and secretion,
In other lineages, terminal differentiation is accompa- extinction of surface major histocompatibility (MHC)
nied by cell cycle arrest in G1, which is largely controlled class II expression, and the development of the secre-
by the D-type cyclin–dependent kinases (CDKs). The tory apparatus (Raynal et al., 1989; Natkunam et al.,
activities of CDKs are in turn regulated by two families 1994). The molecular basis for enhanced immunoglobu-
lin synthesis and secretion has been attributed to tran-
scriptional activation of immunoglobulin genes and§The first two authors contributed equally to this work.
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Figure 2. IL-6 Induces Cell Cycle Arrest
(A) Simultaneous cell cycle arrest and differentiation. CESS cells
were incubated in the presence (1IL-6) or absence (2IL-6) of IL-6
for days indicated, labeled with BrdU and stained for intracellularFigure 1. IL-6 Induces Cell Death in B Cell Terminal Differentiation
IgG (red), BrdU (green), and DAPI (blue) to localize the nucleus.
(A) Selection of terminally differentiated B cells. CESS cells were
(B) Time course of cell cycle arrest and differentiation. The presence
cultured in the presence (1IL-6) or absence (2IL-6) of IL-6 for 5
(Ighi) or absence (Iglo) of enhanced intracellular IgG, and the presencedays. MHC class II–negative (Free) and class II–positive (Bound)
(BrdU1) or absence (BrdU2) of BrdU incorporation were determinedcells wereseparated by the use of HLA-beads, stained for intracellu-
on days of IL-6 treatment as in (A). At least 500 stained cells werelar IgG (red), surface MHC class II (green), and DAPI (blue) to localize
characterized for each time point shown in the histogram, and thethe cell nucleus, and analyzed by immunofluorescence microscopy.
error bars were derived from five samplings in a typical experiment.The small spheres present in the bound fraction represent HLA-
The experiment was performed six times.beads that remained associated with cells after the staining pro-
cedure.
(B) IL-6 induces the death of differentiated B cells. Left: CESS cells
stimulation of IgG- but not IgM-bearing human B lym-were cultured with (1IL-6) or without (2IL-6) IL-6 for 6 days. After
phoblastoid cells. We present results to suggest thatseparation by the use of HLA-beads, the MHC-positive cells (Bound)
the CDK inhibitor p18 INK4c may mediate cytokine signalswere cultured in the absence of IL-6. The MHC class II–negative
cells were cultured in the presence (Free 1IL-6) or absence (Free for cell cycle arrest in B cell terminal differentiation by
2IL-6) of IL-6, as were the control cells without separation (1IL-6, inhibiting CDK6 phosphorylation of pRb.
2IL-6). Right: CESS (MHC class II–positive) and NJBC (MHC class
II–negative) were subject to the HLA bead separation procedure Resultsand cultured in the absence of IL-6. The viable cells were determined
by trypan blue staining (in duplicates) on days after separation as
Terminal Differentiation of B Cells by IL-6indicated.
Is Coupled to Cell Death
Whether IL-6 signaling in B cells led to cell death in the
context of terminal differentiation was investigated indifferential accumulation of immunoglobulin mRNAs
(Raynal et al., 1989). Whether IL-6 also causes differenti- the clonal, IgG1-bearing human lymphoblastoid CESS
cells (Figure 1). IL-6 treatment simultaneously increasedation-coupled cell cycle arrest, however, is not known.
Here we show that cell cycle arrest is coupled to intracellular IgG and reduced surface MHC class II ex-
pression in 20–30% of the cells (Figure 1A), as observedcellular differentiation and cell death in vitro by IL-6
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previously (Natkunam et al., 1994). Of interest, cell prolif-
eration was reduced in response to IL-6. By 6 days of
IL-6 treatment, the number of viable cells was reduced
to10–30% of that of the untreated cells (data not shown).
This appeared to result from apoptosis induced by IL-6
in a dose-dependent manner, as determined by trypan
blue staining (data not shown). To confirm this possibil-
ity, the fate of the differentiated cells was analyzed after
negative selection for the loss of surface MHC class II
expression with the use of HLA beads (anti-MHC class
II antibody conjugated to magnetic beads) (Figures 1A
and 1B). Except for the contaminating MHC class II–
positive cell (5–10%), all differentiated cells (MHC class
II–negative and free of HLA beads) died within 2 days
after separation (Figure 1B). The cell death was specific
to IL-6–differentiated CESS cells because the selection
procedure did not inhibit the proliferation of either un-
treated CESS cells or those that remain undifferentiated
after IL-6 treatment (MHC class II–positive, bound), or
the MHC class II–negative NJBC T cells (free) (Figure
1B). Thus, IL-6 signaling in IgG-bearing B cells leads to
coupled differentiation and cell death in vitro, as ob-
served in terminal differentiation of B cells to plasma
cells in vivo.
IL-6 Signals Lead to Cell Cycle Arrest
and Differentiation
The relationship between cell cycle control and differen-
tiation in B cell terminal differentiation was addressed
by examining simultaneous DNA replication and immu-
noglobulin synthesis in response to IL-6 at the single-
cell level by immunocytochemistry (Figure 2). In the ab-
sence of IL-6, CESS cells cycled and synthesized a low
level of immunoglobulin (5-bromodeoxyuridine-positive
[BrdU1]/Iglo) (Figure 2A). Within 1 day of IL-6 stimulation,
Figure 3. Inhibition of pRb Phosphorylation by IL-6
some cells ceased to incorporate BrdU and increased
(A) IL-6 suppresses pRb phosphorylation. pRb in CESS cells (5 3
immunoglobulin synthesis (BrdU2/Ighi), suggesting co- 106) left untreated (0) or treated with IL-6 (30 U/ml) for days indicated
ordinated cell cycle arrest and differentiation (Figure was analyzed by immunoprecipitation and immunoblotting. The
2A). The proportion of these cells increased as a function phosphorylated forms (ppRB) and hypophosphorylated pRb (pRB)
are indicated.of time of IL-6 treatment, inversely correlating with that
(B) pRb is hypophosphorylated in differentiated cells. pRb in CESSof undifferentiated cells, which continued to synthesize
cells treated with IL-6 for 6 days and unseparated (1IL-6) or sepa-DNA (BrdU1/Iglo) (Figures 2A and 2B). Consistent with
rated into differentiated (Free) and undifferentiated (Bound) popula-
apoptosis following cell cycle arrest and differentiation, tions by the use of HLA-beads was analyzed by immunoprecipitation
the number of BrdU2/Ighi cells declined after maximum and immunoblotting. Each lane represents 5 3 106 cells of each
differentiation at 4–5 days of IL-6 treatment (Figure 2B). population.
(C) Phosphorylation of newly synthesized pRb is inhibited by IL-6.However, cell cycle arrest and differentiation were not
pRb in CESS cells (1 3 107) was labeled with [35S]-methionine for 3obligatorily coupled, because similar increases and de-
hr on days of IL-6 treatment as indicated and analyzed by immuno-creases in cells that ceased to synthesize DNA but failed
precipitation.
to differentiate (BrdU2/Iglo) were also observed in the (D) IL-6 regulates the ratios of pRB to ppRB. The relative intensities
course of IL-6 treatment. In addition, a very minor popu- of steady-state pRB and ppRB as shown in Figure 3A (closed
lation of differentiated cells continued to incorporate squares) and biosynthetically labeled pRB and ppRB as shown in
Figure 3C (open triangles) were determined by scanning and areBrdU (BrdU1/Ighi). No change in BrdU incorporation was
expressed as ratios of pRB to ppRB.detected in the control NJBC cells, the proliferation of
which was not influenced by IL-6 (data not shown). Thus,
IL-6 signaling in IgG-bearing B cells activates two path-
regulator in cooperation with NF–IL-6 (Chen et al., 1996),ways, one that leads to cell cycle arrest and the other
which is significantly regulated by IL-6 in B cells (D. C.to differentiation, and only when the two are coupled
and S. C.-K., unpublished data). Simultaneous cell cycledoes terminal differentiation proceed appropriately.
arrest and differentiation suggest a potential involve-
ment of pRb in IL-6–induced B cell terminal differentia-Phosphorylation of pRb Is Inhibited
tion. Analysis of pRb recovered in immune complexesin Differentiated B Cells
showed that pRb phosphorylation was progressivelyHypophosphorylated pRb causes G1 arrest (Goodrich
et al., 1991) and may also function as a transcriptional suppressed in response to IL-6 (Figure 3A). Accordingly,
Immunity
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after IL-6 treatment (bound) (Figure 4B).While the molec-
ular nature of the 30 kDa protein remains to be deter-
mined, these results suggest that p21 accumulates in
B cells that are terminally differentiated.
Activation of p21, however, did not temporally corre-
late with cell cycle arrest, which occurred within 1 day
of IL-6 treatment (Figure 2A). Although changes in the
p21 level in a small percentage of cells early in thecourse
of IL-6 stimulation may elude biochemical detection, no
association between p21 and CDKs was detected in
differentiated cells (D. C. and S. C.-K., unpublished
data). p21 therefore appears to accumulate in differenti-
ated cells as a consequence rather than a cause of G1
arrest.
Figure 4. p21 Is Activated in IL-6–Differentiated Cells
(A) Time course of p21 activation. p21 in CESS cells (1 3 107), left
untreated (0) or treated with IL-6 for days indicated, was analyzed IL-6 Rapidly Activates the Synthesis of p18
by immunoprecipitation and immunoblotting.
and Its Association with CDK6(B) p21 is activated in differentiated cells. The p21 levels in CESS
To address the potential role of other CDK inhibitors incells left untreated (0) or treated with IL-6 for 5 days and unseparated
(1IL-6) or separated into differentiated (Free) and undifferentiated cell cycle arrest induced by IL-6, we investigated the
(Bound) populations were analyzed by immunoprecipitation and im- regulation of p18INK4c and its interaction with CDK6 in B
munoblotting. Each lane represents 3 3 106 cells of each population. cells in response to IL-6 (Figure 5). Both p18, a CDK
The 14C-labeled molecular weight markers (in kilodaltons) are shown inhibitor of thep16 INK4 family,and CDK6 are preferentially
at left.
expressed in haematopoietic lineage cells (Meyerson(C) The relative intensity of p21 shown in Figure 4A was determined
and Harlow, 1994; Guan et al., 1994; Hirai et al., 1995).by densitometry scanning, with the p21 level in untreated cells arbi-
trarily set as 1. In vitro and in vivo, p18 forms a stable binary complex
with CDK6 and binds CDK4 weakly. p18 has also been
shown to inhibit the kinase activity of CDK6 in vitro
(Guan et al., 1994).while the phosphorylated form of pRb predominated
CDK6 was not regulated by IL-6 in B cells, because itsin cycling B cells, the hypophosphorylated pRb was
level remained unchanged in CDK6 immune complexesfavored by 4 days of IL-6 treatment (Figure 3D). Consis-
recovered from all cells (Figure 5A), and CDK4 was nottent with a role for pRb in B cell terminal differentiation,
detectable in B cells (data not shown). However, a sub-the IL-6–differentiated cells (free) expressed only the
stantial fraction of CDK6 was present in the p18 immunehypophosphorylated pRb, whereas the undifferentiated
complexes recovered from cells treated with IL-6 for 4cells (bound) and the IL-6–treated cells before separa-
days but not from untreated cells (a very low level oftion (bound plus free) expressed all forms of pRb (Figure
CDK6 was detectable in overexposures of the blot). The3B). Phosphorylation of biosynthetically labeled hypo-
interaction between p18 and CDK6 was specific, be-phosphorylated pRb was significantly inhibited by 3
cause it was effectively competed by preincubation ofdays of IL-6 treatment (Figure 3C), correlating with a
either antibody used in immunoprecipitation with its cor-change in the ratios between different forms of pRb to
responding antigenic peptide (Figure 5A). IL-6 thereforefavor the hypophosphorylated form (Figure 3D). Hypo-
markedly enhances the stable interaction between p18phosphorylation of pRb therefore is the result of inhibi-
and CDK6 in B cells.tion of phosphorylation and not dephosphorylation of
The association between p18 and CDK6 should pre-phosphorylated pRb, and itcorrelates with IL-6–induced
cede or be coupled to cell cycle arrest, if p18 mediatescell cycle arrest and differentiation in B cells.
IL-6 signals for the inhibition of pRb phosphorylation by
CDK6 in B cells. We therefore examined the time course
of p18 regulation and the interaction between p18 andp21 Accumulates in Terminally
Differentiated B Cells CDK6 in response to IL-6 (Figure 5B). The p18 level rose
significantly by 24 hr of IL-6 treatment, as determinedInhibition of pRb phosphorylation may result from re-
duced synthesis of cyclins and CDKs, the physiologic by immunoblotting of p18 immune complexes with anti-
p18. Reprobing the blot with anti-CDK6 showed a corre-kinases for pRb (Kato et al., 1993; Meyerson and Harlow,
1994) or activation of CDK inhibitors (Sherr and Roberts, sponding increase of CDK6 present in the p18 immune
complexes. Analogous analysis of CDK6 immune com-1995). The CDK inhibitor p21 has been shown to be
activated by multiple differentiation agents, including plexes confirmed that the CDK6 level was constant,
whereas the amounts of CDK6-associated p18 in-IL-6 (Steinman et al., 1994), and has been implicated in
myocyte terminal cell cycle arrest (Halevy et al., 1995). creased as a function of IL-6 treatment. (More p18 was
detected in the CDK6 immune complexes than in theIn response to IL-6, the level of p21 protein rose in CESS
cells, to 2-fold that of untreated cells by day 4, and then p18 immune complexes because the anti-CDK6 anti-
body was more effective in immunoprecipitation.) Analy-declined (Figures 4A and 4C). In addition, the activation
of p21 as well as an immunoreactive 30 kDa protein sis of biosynthetically labeled proteins recovered in
CDK6 immune complexes further suggested that IL-6occurred only in the differentiated, G1-arrested cells
(20–30%) (free) and not in cells that failed to differentiate induced the association between newly synthesized
p18 Activation in B Cell Terminal Differentiation
51
Figure 5. IL-6 Activates p18 Synthesis and
Its Association with CDK6
(A) IL-6 enhances the association of p18 with
CDK6. p18 and CDK6 were immunoprecipi-
tated with anti-p18-C or anti-CDK6, with or
without preincubation with antigenic pep-
tides, from 1 3 107 CESS cells left untreated
or treated with IL-6 for 5 days. The immune
complexes were analyzed by immunoblotting
with anti-CDK6.
(B) Time course of IL-6–induced p18 activa-
tion and p18-CDK6 association. p18 and
CDK6 were immunoprecipitated with anti-
p18-C or anti-CDK6 from 4 3 107 CESS cells
at hours after IL-6 treatmentas indicated. The
immune complexes were analyzed by se-
quential blotting with anti-p18 (directed
against recombinant p18) and anti-CDK6.
(C) IL-6 activates the association of newly
synthesized p18 and CDK6. [35S]-methionine–
labeled CDK6- and CDK6-associated pro-
teins were immunoprecipitated from CESS
cells (1 3 107) left untreated (0) or treated with
IL-6 for 96 hr, with or without preincubation
with the CDK6 antigenic peptide as indicated.
The proteins in the immune complexes were
resolved by SDS–PAGE. The migrations of
CDK6, p18, and the 14C-labeled protein mark-
ers (in kilodaltons) are marked.
CDK6 and p18, the identities of which wereconfirmed by incorporate BrdU, as compared to BrdU incorporation
in all cells transfected with CD4 alone (Figure 7A, 2IL-6).immunoblotting (Figure 5C and data not shown). These
results suggest that IL-6 increases the synthesis of p18, These results suggest that overexpression of p18, when
reaching a critical concentration, was sufficient tocauseleading to enhanced association between p18 and
CDK6, inhibition of CDK6 phosphorylation of pRb in B G1 arrest of transfected cells.
Next, we examined whether overexpression of p18cells, and cell cycle arrest.
and IL-6 stimulation would lead to coupled cell cycle
arrest and differentiation (Figure 7, 1IL-6). IL-6 differen-Overexpression of p18 Reconstitutes Coupled
Cell Cycle Arrest and Differentiation by IL-6 tiation of SKW cells was not affected by the transfection
procedure, because intracellular IgM levels were in-To investigate further the contribution of p18 to B cell
terminal differentiation, it was necessary to determine creased in z20% of cells transfected with CD4 alone
or p18 and CD4 combined, as in cells left untransfectedthe functions of p18 in B cells in which differentiation
by IL-6 is not coupled to cell cycle regulation. The clonal (compare 1IL-6 results in Figure 7A with those in Figure
6A). Overexpression of p18 in conjuction with IL-6 stimu-IgM-bearing human lymphoblastoid SKW cells, which
represent B lymphocytes earlier in development than lation, however, led to cessation of BrdU incorporation
in 50% of the cells that were enhanced in IgM synthesisthe IgG-bearing CESS cells, are ideal for this purpose.
In response to IL-6, z20% of SKW cells differentiated, (Figure 7A, CD4 1 p18, 1IL-6). These cells died more
rapidly than those that were differentiated and contin-as indicated by increases in intracellular IgM (Figure
6). DNA synthesis, however, continued in differentiated ued to synthesize DNA or cells transfected with CD4
alone (Figure 7A, CD4, 1IL-6), presumably due to G1cells, as determined by BrdU incorporation (Figure 6A),
and cell proliferation and viability was unaffected by IL-6 arrest resulting from overexpression of p18 (data not
shown). Although the number of cells that were simulta-treatment (Figure 6B). Thus, IL-6 signaling in the IgM-
bearing SKW cells, unlike that in the IgG-bearing CESS neously G1-arrested and differentiated remained low
(15–20% of the enriched population), it was significantcells, results in cellular differentiation that is not coupled
to cell cycle arrest. and reproducible in four independent experiments.
Taken together, these results suggest that overexpres-The ability of p18 to induce cell cycle arrest was tested
in SKW cells by transient transfections with an expres- sion of p18 and IL-6 stimulation can reconstitute cou-
pled cell cycle arrest and differentiation of IgM-bearingsion plasmid encoding the human p18 (Guan et al.,
1994). The transfected cells, which also express surface cells.
That p18 overexpression was the cause of cell cycleCD4 from the cotransfected CD4-expression plasmid,
were enriched by the use of anti-CD4 antibodies conju- arrested was confirmed by the detection of p18 in im-
mune complexes recovered from cells transfected withgated to magnetic beads at 48hr posttransfection, when
cell viability was z70%. Analysis of simultaneous IgM p18 and CD4, but not with CD4 alone or the control
pCMV vector or before transfection (Figure 7B, top).synthesis and BrdU incorporation showed that 50% of
the cells transfected with both p18 and CD4 ceased to As anticipated, overexpression of p18 led to a marked
Immunity
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Figure 6. IL-6 Activates IgM Synthesis but
Not Cell Cycle Arrest
(A) IL-6 activates IgM synthesis but not cell
cycle arrest. SKW cells were incubated in the
presence (1IL-6) or absence (2IL-6) of IL-6
(50 U/ml) for 2 days, labeled with BrdU and
stained for intracellular IgM (red), BrdU
(green), and DAPI.
(B) IL-6 does not affect the growth or viability
of IgM-bearing cells. SKW cells were incu-
bated in the presence or absence of IL-6 as
indicated, stained with trypan blue, and
counted to determine cell growth and via-
bility.
increase in the formation of p18–CDK6 complexes, al- Discussion
though a low level of p18–CDK6 was detected in cells
before transfection or after transfection with CD4 or the An In Vitro System to Study Cell Cycle Control
in B Cell Terminal Differentiationcombination of CD4 and the pCMV vector (Figure 7B,
bottom). Thus, p18 appears to be predominantly associ- The mechanism that underlies coordinated cell cycle
control and differentiation in B cell terminal differentia-ated with CDK6 in B cells, and G1 arrest of transfected
IgM-bearing cells was the result of overexpression of tion has remained elusive because in vitro systems that
simultaneously recapitulate these two events were notp18 and the subsequent increases in p18–CDK6 inter-
action. available. In this study, we demonstrated that coupled
Figure 7. Overexpression of p18 and IL-6 Stimulation Reconstitutes Coupled Cell Cycle Arrest and Differentiation
(A) Overexpression of p18 causes cell cycle arrest. SKW cells were transfected with expression plasmids encoding CD4, or CD4 and p18
together, and cultured in the presence (1IL-6) or absence of IL-6 (2IL-6) for 48 hr as indicated. BrdU was added to the medium for the last
24 hr before staining for intracellular IgM (red), BrdU (green), and DAPI (blue). The small red spheres represent the anti-CD4 magnetic beads
used for selecting transfected cells that remained after the staining procedure. Arrowheads mark representative CD41BrdU2IgMlo cells
transfected with CD4 and p18; CD41BrdU1 IgMhi cells transfected with CD4 and treated with IL-6; and CD41BrdU2IgMhi and CD41BrdU1IgMhi
cells transfected with both CD4 and p18 and treated with IL-6. At least 500 cells were characterized for each panel shown. This experiment
was performed four times.
(B) Enhanced expression of p18 and p18-CDK6 association in p18-transfected cells. SKW cells (8 3 106) were transfected with various amounts
(micrograms) of CD4 and p18 expression plasmids, as well as the vector for p18 as indicated. Immunoprecipitation with anti-p18 peptide
antibody and sequential blotting with anti-p18 and anti-CDK6 antibodies were performed as described in Figure 5B. This experiment was
performed four times.
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differentiation and cell death could be reconstituted in such as p21 also were increased in IL-6–differentiated
cells, the timing of p21 activation and the lack of itsvitro by IL-6 stimulation of human IgG-bearing lym-
phoblastoid cells. The clonal, Epstein-Barr virus (EBV)– interaction with CDKs do not support a causative role
for p21 in IL-6–induced cell cycle arrest (Figure 4). Third,immortalized human B cells mimic late-stage mature B
lymphocytes activated by antigen and T cell costimula- overexpression of p18 in IgM-bearing SKW cells led to
enhanced p18–CDK6 association and G1 arrest, and intion (Banchereau et al., 1994; Kempkes et al., 1995) and
are thus poised for terminal differentiation. The coordi- cooperation with IL-6 stimulation, it reconstituted cou-
pled cell cycle arrest and differentiation (Figure 7). Ini-nated differentiation and cell death in response to IL-6
suggest that IL-6 signaling reactivates the B cell terminal tially identified as a CDK6-associated protein in the
yeast two-hybrid system, p18 shares a significant pro-differentiation program and reverses immortalization of
B cells by EBV. This in vitro differentiation system should tein-sequence similarity with a conserved domain pres-
ent in proteins of the Notch family, which are crucial fortherefore provide a valuable model for investigating the
mechanisms that underlie B cell terminal differentiation, the determination of cell fate in Drosophila development
(Guan et al., 1994; Hirai et al., 1995). p18 is markedlyIL-6 signal transduction in B cells, and the interaction
between IL-6 and EBV. Furthermore, the ability to enrich activated in myogenic differentiation, suggesting that it
may also have a role in the terminal differentiation ofdifferentiated plasma cells to near homogeneity offers
an opportunity to address the fate of the differentiated cells of other lineage (Franklin and Xiong, 1996). Thus,
although our data do not exclude the potential contribu-cells at the biochemical and molecular levels with confi-
dence. tion of other CDK inhibitors to IL-6 signaled cell cycle
arrest, they strongly suggest that p18 has a pivotal roleCell cycle arrest represents one of the primary biologi-
cal consequences of IL-6 signaling in late-stage mature in regulating cell cycle progressionvia inhibition of CDK6
phosphorylation of pRb in B cell terminal differentiation.B cells, as revealed by single-cell analysis of CESS cells
(Figure 2). Of the cells exited from the cell cycle, 50%
were increased in immunoglobulin synthesis and pro-
IL-6 Responses in B Cellsceeded to programmed cell death, thus mimicking pro-
Cell cycle arrest was not observed in IgM-bearing cells,ductive terminal differentiation of B cells in vivo. The
including the SKW cells, although they responded tofate of the remainder, which were growth-arrested but
IL-6 and increased in immunoglobulin synthesis as didfailed to differentiate, was less clear because selection
the IgG-bearing CESS cells (Figure 6; Z. Liu and S. C.-K.,for this population has not been possible. Since these
unpublished data). Integration of the two IL-6 signalingtwo populations increased and decreased in synchrony
pathways, one of which leads to differentiation and theduring IL-6 treatment (Figure 2B), it is unlikely that one
other to cell cycle control, therefore appears to be con-served as the precursor for the other. Rather, our data
tingent on the developmental stage of the B cells.suggest that once B cells withdraw from the cell cycle
Whether IL-6 signaling in IgM-bearing cells also resultsin response to IL-6, they are committed to a pathway
in reduction of surface MHC class II expression, anotherleading to death. If coupled in a timely way to the differ-
hallmark of terminal B cell differentiation seen in CESSentiation pathway, productive differentiation ensues.
cells, is under investigation. Within each of the clonalOtherwise, terminal differentiation is nonproductive(that
IgG- and IgM-bearing cell populations, however, differ-is, fails to activate immunoglobulin synthesis) but none-
entiation by IL-6 as determined by increases in immuno-theless also ends in cell death.
globulin synthesis is limited to 20–30% of cells (Figures
1 and 6). The molecular basis for this phenomenon is
presently not known. Differentiation of B cells by IL-6 isRole of CDK Inhibitors in B Cell
Terminal Differentiation not isotype- or promoter-restricted because IL-6 en-
hances immunoglobulin synthesis in polyclonal tonsillarCell cycle arrest is thus linked to cell death as well as
cellular differentiation in terminal differentiation of late- B lymphocytes after activation by EBV (Natkunam et al.,
1994). It is, however, time-dependent and subject tostage B cells to plasma cells. As a first step toward
understanding the mechanism that governs cell cycle negative-feedback regulation, because prolonged ex-
posure to IL-6 leads to unresponsiveness in both IgG-arrest in B cell terminal differentiation, we investigated
the regulation of three classes of gene products that and IgM-bearing cells (Natkunam et al., 1994; Z. Liu and
S. C.-K., unpublished data). Since the heterogeneity ofare crucial for the G1–S transition: pRb, CDKs, and CDK
inhibitors. On the basis of the findings that phosphoryla- IL-6 responsiveness and the feedback regulation cannot
be accounted for by differences in the density of thetion of pRb was inhibited in B cells in response to IL-6
and that differentiated,G1-arrested cells expressed only IL-6 receptor (Z. Liu and S. C.-K., unpublished data), a
major control for IL-6 responsiveness in B cells must liethe hypophosphorylated form of pRb (Figure 3), pRb is
likely to have an important role in mediating the IL-6 further downstream in the IL-6 signaling pathways. The
JAK-STAT (Janus kinase–signal transducer and activa-signals for cell cycle arrest in B cells.
The CDK inhibitors, in particular p18, are potentially tor of transcription) pathway (Schindler and Darnell,
1995) is a potential candidate. It is well established thatthe primary targets for IL-6 signals that lead to inhibition
of pRb phosphorylation and cell cycle arrest. First, while IL-6 rapidly activates the latent transcription factors
STATs in B cells (Zhang et al., 1995) as in cells of otherCDK6 and CDK4 were not regulated, IL-6 activated the
synthesis of p18 in IgG-bearing cells, concomitant with lineages (Schindler and Darnell, 1995). While the B cell–
specific target genes of STATs have not yet been identi-enhanced association of p18 with CDK6 and cell cycle
arrest (Figure 5). Second, although other CDK inhibitors fied, serine phosphorylation of STATs, as we have
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beads (2 3 108) that had been washed four times in the same me-shown, confers at least one level of regulation of STAT
dium, and incubated with gentle rotation at 48C for 10 min. The MHCactivity (Zhang et al., 1995). Elucidating the serine kinase
class II–negative cells were free from the beads and collected inpathway(s) that are coupled to the JAK-STAT pathway
the medium after removal of the beads with use of a magnetic plate.
and the developmental stage-specific target genes of They were further enriched by repeating the procedure once more
STATs in B cells should help to elucidate the molecular using freshly washed beads. The twice negatively selected cells
were then transferred to a fresh flask and separated from contami-determinants for IL-6 response in B cells.
nating beads with use of a magnetic plate. This resulted in a popula-
tion in which greater than 90% of the cells were MHC class II–
CDK Inhibitors and B Cells Neoplasia negative. The MHC class II–positive cells (bound to beads) were
resuspended in 30 ml of separation medium. After removal of con-The molecular basis for plasma cell tumors, multiple
taminating MHC class II–negative cells present in themedium, nearlymyelomas in humans, and plasmacytomas in mice is
100% of the cells that bound to the beads were MHC class II–not understood despite the knowledge that IL-6 is nec-
positive.
essary (Hilbert et al., 1995) and sufficient (Nordan and
Potter, 1986; Suematsu et al., 1992) to induce plasmacy- Transfection and Selection of Transfected Cells
tomas in mice of the appropriate genetic background. SKW cells maintained in the log phase of growth (2–5 3 105/ml)
Accordingly, IL-6 promotes the growth of plasmacytoma were transfected by electroporation essentially according to Hatada
et al. (E. Hatada, S. C.-K., and C. Scheidereit, unpublished data).and myeloma cells in vitro (Nordan and Potter, 1986).
After replacement of the culture medium at 5 hr before transfection,Within the context of B cell terminal differentiation, how-
the cells were collected and resuspended at 2 3 107 cells/ml inever, IL-6 signaling leads to cell death following cell
complete medium in room temperature. To each 0.4 ml of the cell
cycle arrest in IgG- but not IgM-bearing human B cells suspension, 15 mg of DNA (2 mg/ml in 10 mM Tris and 1 mM EDTA)
(Figures 1 and 2). What then determines the IL-6– was added and mixed gently. Following electrophoration at 220 V,
induced proliferation of tumor-derived plasmacytoid 750 mF with a Bio-Rad Gene Pulser II, the cells were immediately
transferred to a small culture flask containing 10 ml of prewarmedcells and the death of terminally differentiated plasma
medium. The culture medium was replaced at 24 hr, and thecells? Mutations and deletions of at least one CDK inhib-
transfected cells were analyzed at 48 hr after transfection, whenitor, p16, have been observed in primary tumors (Spruck
z70% of the cells were viable. The expression plasmids used in
et al., 1994). Deletion of both p16 and p19 in mice has led the transfections were pCMV–p18, which contains a cDNA encoding
to spontaneous tumors, in particular B cell lymphoma the human p18 (Guan et al., 1994); pCDNA-3, the control pCMV
(Serrano et al., 1996). Activation of p18 synthesis and vector; and pCDNA-3/T4, which encodes human CD4 (kindly pro-
vided by Dr. Dan Littman) as a surface marker for the selection ofassociation between p18 and CDK6 in differentiation-
transfected cells.coupled cell cycle arrest (Figures 2 and 5) and induction
Transfected cells expressing surface CD4 were selected by theirof cell cycle arrest by overexpression of p18 (Figure
interactions with anti-CD4 antibodies conjugated to magnetic beads
7) suggest that CDK inhibitors play a central role in (Dynal, Lake Success, New York). At 2 days after transfection, SKW
controlling the progression of cell cycle in mature B cells (1 3 107) were collected by centrifugation and washed twice
cells. The in vitro B cell terminal differentiation system in separation medium (RPMI supplemented with 2% FCS). The cell
pellet was resuspended in 2 ml of separation medium containingshould provide a useful reference for studying plasma
beads (1.5 3 106) that had been washed 4 times with the samecell tumors. Further investigations of the interplay be-
medium, and incubated with gentle rotation at 48C for 15 min. Thetween CDKs and their inhibitors and the biological con-
CD41 cells (bound to beads) were separated from the CD42 cells
sequences in B cells should also help to elucidate the (free from beads) by the use of a magnetic plate. After removal of
molecular mechanism that underlies deregulated prolif- the supernatant, which contains the CD42 cells, the CD41 cells were
eration in plasmacytomas. washed once and collected.
Immunofluorescence MicroscopyExperimental Procedures
Immunofluoresence microscopy was performed essentially as de-
scribed (Natkunam et al., 1994). Cells were collected and washedCells and Cytokine
three times with the PBS/BSA buffer (137 mM NaCl, 2.7 mM KCl, 8
Cells of the EBV-immortalized human B lymphoblastoid cell lines
mM Na2HPO4, 1.4 mM KH2PO4 [pH 7.4], 1 mM MgCl2, 0.02% NaN3,CESS (IgG-bearing) and SKW (IgM-bearing), and NJBC cells, deriva-
and 1% BSA). The PBS/BSA buffer was used in all subsequent steps
tives of human Jurkat T cells expressing the high affinity human
unless otherwise indicated. For simultaneous detection of surface
IL-6 receptor, have been described (Hsu et al., 1994; Natkunam
MHC class II and intracellular IgG, cells were incubated with a mouse
et al., 1994). They were maintained in RPMI 1640 medium (Life
monoclonal antibody (MAb) CA2.06 (1:400, kindly provided by Dr.
Technologies, Inc.) supplemented with 10% heat-inactivated fetal
M. Peterlin) on ice for 30 min and rinsed. The bound antibody was
calf serum (Hyclone, Logan, Utah), 2 mM L-glutamine, penicillin (100
detected by incubation on ice for 30 min with polyclonal fluorescein
U/ml), streptomycin (100 U/ml) and 2 mM nonessential amino acids.
isothiocyanate (FITC)–conjugated sheep anti-mouse antibodies
In some cultures, human IL-6 synthesized in a baculovirus vector
(1:50, Cappel, Durham, North Carolina), which had been preab-
(May et al., 1991) was added (40 U/ml) for time indicated, unless
sorbed against CESS cells to eliminate cross-reactivity with human
otherwise specified. The cell viability was determined by staining
IgG. After rinsing, the cells (105) were spun onto a slide with use of
with trypan blue (Life Technologies, Inc.).
a Cytospin centrifuge (Shandon, Pittsburgh, Pennsylvania) at 200
rpm for 4 min and permeablized in a freshly prepared and chilled
solution of methanol and glacial acetic acid (95:5) at 2208C for 20Separation of MHC Class II–Negative and Class
II–Positive Cells min. The fixed cells were rinsed with TBST buffer (10 mM Tris-HCl
[pH 8.0], 150 mM NaCl, 0.02% Tween-20, and 0.02% NaN3) andMHC class II–negative and class II–positive cells were separated
according to their interactions with anti-MHC class II antibodies incubated with TBST containing 3% BSA (TBST/BSA) at room tem-
perature for 10 min to block cross-reactivity. In all subsequent steps,conjugated to magnetic beads (HLA beads) (Dynal, Lake Success,
New York). At days 5 or 6 of culturing in the presence of IL-6 (40 TBST/BSA was used for antibody dilution, and TBST was used
for rinsing cells unless otherwise indicated. Intracellular IgG wasU/ml), CESS cells (1 3 108) were collected and washed twice in the
separation medium (RPMI supplemented with 2% FCS). The cell detected by incubation with affinity purified polyclonal rhodamine-
conjugated goat anti-human IgG antibodies (1:1000, Cappel) at 378Cpellet was resuspended in 3 ml of separation medium containing
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for 40 min. The cells were then rinsed twice with TBST and once with 3 mg/ml aprotinin, 1 mg/ml antipein, 0.3 mg/ml leupeptin, and 0.5%
NP-40 on ice for 15 min (Datto et al., 1995). The lysates were clearedTBST (pH 8.4) and sealed under coverslip in 4-diazabicyclo(2,2,2)
octane (Sigma, St. Louis, Missouri) in glycerol (2.5% w/v). Visualiza- by centrifugation at14,000 rpm for 15 min. They were then incubated
at 48 for 2 hr with affinity- purified antibodies: a mouse monoclonaltion and photography were performed with the use of a Zeiss Axio-
phot microscope. antibody against a GST-human p21 fusion protein (clone 6B6, Phar-
Mingen, San Diego), or rabbit polyclonal antibodies for the carboxyl
terminal amino acid residues CLMQANGAGGATNLQ of human p18BrdU Labeling and Detection
(anti-p18C or 11256) (Guan et al., 1994), or CKENLDSHLPPSQNTFor simultaneous detection of intracellular IgG and BrdU, CESS cells
SELNTA (306–326) of human CDK6 (C-21, Santa Cruz). The immunewere cultured in complete medium conaining BrdU (10 mM) for 24
complexes were collected after incubation with Protein A–seph-hr, in the presence or absence of IL-6 (40 U/ml). They were then
arose CL-4B beads and washed four times with the lysis buffer B.collected and stained with rhodamine-conjugated goat anti-human
To control for the specificity of immunoprecipitation, the antibodiesIgG antibodies (1:200, Cappel) at 378C for 1 hr as described above.
were preincubated with a molar excess of antigenic peptides inThe stained cells were rinsed in TBST, denatured in 2 N HCl at room
10–100 ml of lysis buffer B at room temperature for 2 hr beforetemperature for 10 min, and neutralized in freshly prepared, 0.1 M
immunoprecipitation. The proteins were resolved by SDS–PAGE onsodium borate buffer (pH 8.5) at room temperature for 10 min as
a 10% gel and transferred onto a nitrocellulose membrane. Afterdescribed (Hardy and Reynolds, 1991). The cells were then rinsed
blocking nonspecific binding with PBS containing 0.1% Tween 20once with TBST, once with TBST/BSA, both at room temperature
and 5% nonfat milk overnight, immunoblotting was performed byfor 10 min, and incubated with a mouse anti-BrdU MAb (1:500 in
incubation with the indicated antibody at room temperature for 60TBST/BSA, DAKOPATTS, Denmark) at 378C for 40 min. The stained
min and detected by ECL.cells were rinsed by incubation in TBST/BSA at room temperature
for 10 min. The bound anti-BrdU antibody was detected by incuba-
tion with FITC-conjugatedsheep anti-mouse antibodies (1:500, Cap- Biosynthetic Labeling and Immunoprecipitation
pel) at 378C for 40 min. The cells were then rinsed once with TBST, For biosynthetic labeling, 1 3 107 cells were washed once with RPMI
counterstained with DAPI (49,6-diamino-29-phenylindole dihydro- medium free of methionine and serum at room temperature and
chloride, 17 mM in TBST, Boehringer Mannheim, Germany), and incubated in 2 ml of methionine-free RPMI supplemented with 10%
rinsed with TBST (pH 8.4), all at room temperature for 10 min, before dialyzed fetal calf serum at 378C for 30 min. [35S]-methionine (specific
visualization and photography as described above. activity 10 mCi/ml, DuPont–New England Nuclear) was added to 100
For simultaneous detection of intracellular IgM and BrdU, SKW mCi/ml, and incubation was continued for 3–4 hr as indicated. pRb
cells were also cultured in the presence of BrdU for 24 hr before was immunoprecipitated from cell lysates and resolved by SDS–
analysis (or from 24 to 48 hr after transfection), with or without PAGE as described above. To detect CDKs and CDK inhibitors,
IL-6 (50 U/ml). In some cultures, IL-6 was added immediately after cells were lysed by incubation on ice for 15 min in 0.5 ml of lysis
transfection. After selection with anti-CD4 beads 2 days after trans- buffer C which contains 50 mM Tris. HCl (pH 7.4), 150 mM NaCl, 20
fection, the CD41 cells were rinsed in PBS/BSA supplemented with mM EDTA, 50 mM NaF, 0.1 mM Na3VO4, 1 mM PMSF, 25 mg/ml
5% goat serum to reduce the background, spun onto slides, perme- aprotinin, 1 mg/ml antipein, 25 mg/ml leupeptin, and 0.5% NP-40
abilized, and incubated with rhodamine-conjugated goat anti- (Xiong et al., 1992). Lysates were cleared by centrifugation at 14,000
human IgM antibodies (1:50, Southern Biotechnology Associates, rpm for 15 min and incubated with 1 ml of a preimmune rabbit serum
Birmingham, Alabama) at 378C for 1 hr. The stained cells were dena- at 48C for 60 min. Nonspecific immune complexes were removed
tured and neutralized as described above for detection of BrdU in by incubation with Protein A–sepharose CL-4B beads and centrifu-
CESS cells. The cells were then rinsed once with TBST and once gation. p18 and CDK6 was immunoprecipitated by incubation at
with TBST/BSA supplemented with 5% goat serum (both at room 48C for 4 hr with 1 ml of anti-p18C and CDK6 as described above.
temperature for 10 min) and incubated with a FITC-conjugated The immune complexes were collected and washed 4 times with
mouse anti-BrdU MAb (1:10 in TBST/BSA/Goat Serum, Boehringer lysis buffer C before resolving by SDS–PAGE on a 15% gel. 14C-
Mannheim) at 378C for 40 min. The cells were then rinsed, counter- labeled molecular weight markers (DuPont–New England Nuclear)
stained with DAPI, and analyzed as described for CESS cells. were used in electrophoresis, and the gels were dried before autora-
diography.
Immunoprecipitation and Immunoblotting
To detect pRb by immunoprecipitation and immunoblotting, cells
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